Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sjögren's Syndrome: a randomized, double-blind, placebo controlled cross-over study
Open Access
- 31 December 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Negative Results in BioMedicine
- Vol. 6 (1), 11
- https://doi.org/10.1186/1477-5751-6-11
Abstract
Background: Matrix metalloproteinases (MMPs) are proteolytic enzymes that may contribute to tissue destruction in Sjögren's syndrome (SS). Low-dose doxycycline (LDD) inhibits MMPs. We evaluated the efficacy of LDD for the subjective symptoms in primary SS patients. This was a randomized, double blind, placebo controlled cross-over study. 22 patients were randomly assigned to receive either 20 mg LDD or matching placebo twice a day for 10 weeks. The first medication period was followed by 10-week washout period, after which the patient received either LDD or placebo, depending on the first drug received, followed by the second washout period. Stimulated saliva flow rates and pH were measured before and after one and ten weeks of each medication and after washout periods. VAS scale was used to assess the effect of LDD and placebo on following six subjective symptoms: xerostomia; xerophtalmia; difficulty of swallowing; myalgia; arthralgia; and fatigue. The effect was evaluated for each medication and washout period separately. Results: Overall, the effects of medications on subjective symptoms were minor. Wilcoxon test demonstrated increased fatigue with LDD during medication (p < 0.05). The differences may, however, reflect normal fluctuation of symptoms in SS patients. Conclusion: LDD may not be useful in reducing the primary SS symptoms.Keywords
This publication has 29 references indexed in Scilit:
- Subantimicrobial dose doxycycline in the treatment of recurrent oral aphthous ulceration: a pilot studyJournal of Oral Pathology & Medicine, 2007
- Sjögren's syndrome – managing oral and systemic symptoms via a multi‐disciplinary approach*Oral Diseases, 2004
- Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndromeRheumatology, 2004
- Ultrasonography of salivary glands in primary Sjogren's syndrome. A comparison with magnetic resonance imaging and magnetic resonance sialography of parotid glandsRheumatology, 2004
- Suppression of tumor necrosis factor α–induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down‐regulation of nuclear factor κB: A possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patientsArthritis & Rheumatism, 2002
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- A double‐blind, randomized, placebo‐controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis siccaArthritis & Rheumatism, 2002
- The treatment of Sjögren's syndrome patients with Pilocarpine-tabletsScandinavian Journal of Rheumatology, 2001
- Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial MechanismsAdvances in Dental Research, 1998
- Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren's syndromeMatrix Biology, 1998